Concepedia

Yagmur Caliskan

YC

6

Publications

950

Citations

6

H-Index

2017

Active since

Affiliations

Alexion Pharmaceuticals (United States)(Current)

National Hospital Organization Hanamaki Hospital

International University of Health and Welfare

Wellcome Trust

University of Münster

Yagmur Caliskan is an author at Alexion Pharmaceuticals (United States) specializing in medicine, pharmacology, and radiation oncology.

Top concepts

Publications per year

2017–2020

6

Publications

6

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

, , +3

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

Renato Mantegazza, Gil I. Wolfe, Srikanth Muppidi et al. · Neurology · 2020 · 74 citations · Full text

A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co-loaded liposomal formulation

Yagmur Caliskan, Ali Deniz Dalgıç, Selin Gerekçi et al. · International Journal of Pharmaceutics · 2018 · 45 citations · Full text

, , +5

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara et al. · Multiple Sclerosis and Related Disorders · 2020 · 37 citations · Full text

Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

Saiju Jacob, Hiroyuki Murai, Kimiaki Utsugisawa et al. · Therapeutic Advances in Neurological Disorders · 2020 · 26 citations · Full text

Rows per page

1–5 of 6